The stock is up 266% ($109.15) since this interview and with the covid variants likely leading to another surge in testing the stock has a lot of room to grow. The variants have already caused businesses, agencies, and certain states to implement measures requiring negative Covid tests to enter facilities, which will likely lead to another surge in demand for Fulgent's services.
Plus, the company over the last year and a half have large return on investment capital margins showcasing that it's an efficient company, in comparison to many other hyped-up stocks that have horrible ROIC margins. Free cash flow has also
increased substantially in that time period, and so they have ample cash to invest past the Covid surge. In addition, their revenue and net income/profits, and profit margins continue to grow every quarter.
And so, given all these factors plus earnings being announced on the 9th (the stock is up 16% this week) Fulgent is a stock jokers could put money in either on some short or long term tip.